AvantGen is a San Diego-based biotechnology company founded in 2006 with Therapeutic and Research & Diagnostic divisions
With its proprietary and robust yeast display system, large natural human antibody database, fully human antibody (Germliner™) libraries and screening technologies, AvantGen’s Therapeutic Division is dedicated to novel human antibody discovery, antibody humanization, antibody affinity maturation and optimization, for therapeutic development. AvantGen collaborates with pharmaceutical and biotechnology companies to facilitate and speed their path to antibody-based therapeutic development through services, partnerships, and licensing.
AvantGen provides service, partnership, and licensing opportunities for therapeutic antibody development, including novel human antibody discovery, antibody humanization and optimization.
AvantGen provides service and partnership opportunities for novel rabbit monoclonal antibody discovery. The rabbit monoclonal antibodies generated with our technology exhibit superior affinity and selectivity suitable for sensitive diagnostic development and research uses.
AvantGen has developed many antibody clones with superior affinity and specificity. The antibodies are characterized at the DNA sequence level and many of them have been validated to be suitable for diagnostic use, while many others have been shown to work well for research applications such as ELISA, Western Blot and immunoprecipitation.